Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health announced EU IVDR certification for its Guardant360 CDx liquid biopsy, allowing comprehensive genomic profiling across all solid cancers.
Certification by TÜV SÜD provides a significant milestone, ensuring compliance with stricter EU regulatory standards. This enables broader adoption and faster access to genomic profiling, aiding personalized treatment for advanced cancer patients.
Guardant360 CDx identifies somatic mutations using a blood sample, facilitating targeted therapies for non-small cell lung and breast cancer.
Clinical studies suggest that targeted therapies result in improved progression-free survival and higher response rates.
Adoption of genomic profiling with IVDR-certified liquid biopsy can address challenges like insufficient tissue for molecular profiling, ultimately benefiting more cancer patients.
Since its introduction, Guardant360 has been widely accepted, with over 500,000 tests performed and more than 400 peer-reviewed publications.
Guardant Health (Nasdaq: GH) announced on April 22, 2024, that its Compensation Committee has approved the granting of restricted stock units (RSUs) and non-qualified stock options to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. This move, compliant with Nasdaq Listing Rule 5635(c)(4), involves RSUs representing 215,601 shares of common stock to 94 employees and stock options to purchase 98,076 shares to three employees. The RSUs and stock options have a vesting schedule tied to continued employment, with stock options priced at $24.00 per share, the closing price on May 13, 2024.
Guardant Health (Nasdaq: GH) will present real-world data supporting the performance of its Shield™ blood test for colorectal cancer (CRC) screening at the 2024 Digestive Disease Week (DDW) in Washington, DC. The Shield test aims to increase CRC screening rates by offering a more convenient and less unpleasant method compared to traditional options. Presentations will include data showing improved screening rates and early detection of CRC. Initial results from the ECLIPSE study, validating Shield’s performance, were unveiled at the 2023 DDW, leading to a premarket approval (PMA) application to the FDA. An FDA Advisory Panel is set to review this application on May 23, 2024.
Guardant Health reported a 31% increase in revenue for the first quarter of 2024 compared to the same period in 2023. The company achieved significant revenue growth in precision oncology, driven by increased testing volume and reimbursement rates. Despite a decrease in free cash flow, Guardant Health raised its 2024 revenue guidance to $675-$685 million, showcasing a positive outlook for the year. The company also highlighted key milestones achieved in clinical data validation, product launches, and publication impact.
Guardant Health, Inc. (Nasdaq: GH) will participate in upcoming investor conferences including the BofA Securities 2024 Healthcare Conference and Leerink Partners 2024 Healthcare Crossroads Conference. Interested parties can access live and archived webcasts of the sessions on the company website.
Guardant Health, Inc. (Nasdaq: GH) has achieved a significant milestone by surpassing 500 peer-reviewed publications featuring its technology in esteemed scientific journals. These publications have had a profound impact on the oncology field, validating Companion Diagnostic claims and driving changes in NCCN guidelines. The company's accelerated publication rate of approximately 100 publications annually highlights its leadership in liquid biopsy research.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
